Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis

[1] Schweitzer A(2015)Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013 Lancet 386 1546-1555

[2] Horn J(2019)Epidemiology and management of hepatocellular carcinoma Gastroenterology 156 477-91.e1

[3] Mikolajczyk RT(2018)Temporal improvement in survival of patients with hepatocellular carcinoma in a hepatitis B virus-endemic population J Gastroenterol Hepatol 33 475-483

[4] Krause G(2014)Clinical outcomes of a cohort series of patients with hepatocellular carcinoma in a hepatitis B virus-endemic area J Gastroenterol Hepatol 29 820-829

[5] Ott JJ(2019)KASL clinical practice guidelines for management of chronic hepatitis B Clin Mol Hepatol 25 93-159

[6] Kulik L(2019)Hepatocellular carcinoma N Engl J Med 380 1450-1462

[7] El-Serag HB(2018)Epidemiology of liver cancer in South Korea Clin Mol Hepatol 24 1-9

[8] Kim BH(2014)Alternative response criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib Oncologist 19 394-402

[9] Lim YS(2016)Challenges of advanced hepatocellular carcinoma World J Gastroenterol 22 7645-7659

[10] Kim EY(2004)BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 7099-7109

[1] Schweitzer A(2015)Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013 Lancet 386 1546-1555

[2] Horn J(2019)Epidemiology and management of hepatocellular carcinoma Gastroenterology 156 477-91.e1

[3] Mikolajczyk RT(2018)Temporal improvement in survival of patients with hepatocellular carcinoma in a hepatitis B virus-endemic population J Gastroenterol Hepatol 33 475-483

[4] Krause G(2014)Clinical outcomes of a cohort series of patients with hepatocellular carcinoma in a hepatitis B virus-endemic area J Gastroenterol Hepatol 29 820-829

[5] Ott JJ(2019)KASL clinical practice guidelines for management of chronic hepatitis B Clin Mol Hepatol 25 93-159

[6] Kulik L(2019)Hepatocellular carcinoma N Engl J Med 380 1450-1462

[7] El-Serag HB(2018)Epidemiology of liver cancer in South Korea Clin Mol Hepatol 24 1-9

[8] Kim BH(2014)Alternative response criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib Oncologist 19 394-402

[9] Lim YS(2016)Challenges of advanced hepatocellular carcinoma World J Gastroenterol 22 7645-7659

[10] Kim EY(2004)BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 7099-7109